MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Mepolizumab (Nucala®)

Selected References:

  • Kasuya A, et al. 2019. Successful control of severe eosinophilic granulomatosis with polyangiitis in pregnancy and perinatal period: A use of mepolizumab. The Journal of Dermatology 46(9):e309-e311.
  • Nucala® Prescribing Information. Revised 1/2022. Available online at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF.
  • Shakuntulla F, Chiarella SE. 2022. Safety of Biologics for Atopic Diseases During Pregnancy. J Allergy Clin Immunol Pract.10(12):3149-3155.
  • Sitek AN, et al. 2023. Risks and safety of biologics: A practical guide for allergists. World Allergy Organ J. 16(1):100737.
  • Smith DA, et al. 2011. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 50(4):215–27.
  • Vittorakis SK, et al. 2022. Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy. Respir Med Case Rep. 28;41:101785.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.